[1]
Banerjee, S.R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Green, G.; Fox, J.J.; Horti, A.; Mease, R.C.; Pomper, M.G. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J. Med. Chem., 2010, 22, 5333-5341.
[2]
Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A. Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S.; Haberkorn, U.; Zechmann, CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40, 486-495.
[3]
Sanli, Y.; Kuyumcu, S.; Sanli, O.; Buyukkaya, F.; İribaş, A.; Alcin, G.; Darendeliler, E.; Ozluk, Y.; Yildiz, S.O.; Turkmen, C. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann. Nucl. Med., 2017, 31, 709-717.
[4]
Verburg, F.A.; Pfister, D.; Drude, N.I.; Mottaghy, F.M.; Behrendt, F.F. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer. Nuklearmedizin, 2017, 18, 225-232.
[5]
Bluemel, C.; Krebs, M.; Polat, B.; Linke, F.; Eiber, M.; Samnick, S.; Lapa, C.; Lassmann, M.; Riedmiller, H.; Czernin, J.; Rubello, D.; Bley, T.; Kropf, S.; Wester, H.J.; Buck, A.K.; Herrmann, K. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin. Nucl. Med., 2016, 41, 515-521.
[6]
Afshar-Oromieh, A.; Haberkorn, U.; Eder, M.; Eisenhut, M.; Zechmann, C.M. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECH. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 1085-1086.
[7]
Kratochwil, C.; Giesel, F.L.; Eder, M.; Afshar-Oromieh, A.; Benesova, M.; Mier, W.; Kopka, K.; Haberkorn, U. [177Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42, 987-988.
[8]
Singh, A.; Kulkarni, H.R.; Baum, R.P. Imaging of prostate cancer using 64Cu-Labeled Prostate-specific membrane antigen ligand. PET Clin., 2017, 12, 193-203.
[9]
Cantiello, F.; Gangemi, V.; Cascini, G.L.; Calabria, F.; Moschini, M.; Ferro, M.; Musi, G.; Butticè, S.; Salonia, A.; Briganti, A.; Damiano, R. Diagnostic Accuracy of 64Copper prostate-specific membrane antigen positron emission tomography/computed tomography for primary lymph node staging of intermediate- to high-risk prostate cancer: our preliminary experience. Urology, 2017, 106, 139-145.
[10]
Umbricht, C.A.; Benešová, M.; Schmid, R.M.; Türler, A.; Schibli, R.; van der Meulen, N.P.; Müller, C. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res., 2017, 7, 9.
[11]
Strele-Trieb, P.; Dunzinger, A.; Sonnberger, M.; Wolfsgruber, J.; Pichler, R. Uptake of 68Ga-Prostate-specific membrane antigen pet in adrenal gland: a potential pitfall. Clin. Nucl. Med., 2017, 43, 50-51.
[12]
Jochumsen, M.R.; Dias, A.H.; Bouchelouche, K. Benign traumatic rib fracture: a potential pitfall on 68Ga-prostate-specific membrane Antigen PET/CT for Prostate Cancer. Clin. Nucl. Med., 2018, 43, 38-40.
[13]
Gykiere, P.; Goethals, L.; Everaert, H. Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET/CT. Clin. Nucl. Med., 2016, 41, e346-e347.
[14]
Elri, T.; Aras, M.; Salihoglu, Y.S.; Erdemir, R.U.; Cabuk, M. A potential pitfall in the use of 68Ga-PSMA PET/CT: anthracosis. Rev. Esp. Med. Nucl. Imagen Mol., 2017, 36, 65-66.
[15]
Kanthan, G.L.; Drummond, J.; Schembri, G.P.; Izard, M.A.; Hsiao, E. Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin. Nucl. Med., 2016, 41, 331-332.
[16]
Calabria, F.; Gangemi, V.; Gullà, D.; Schillaci, O.; Cascini, G.L. 64Cu-PSMA uptake in meningioma: a potential pitfall of a promising radiotracer. Rev. Esp. Med. Nucl. Imagen Mol., 2017, 36, 335-336.
[17]
Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.; Cordon-cardo, C. Prostate specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 1997, 3, 81-85.
[18]
Shreve, P.D.; Anzai, Y.; Wahl, R.L. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics, 1999, 19, 61-77.
[19]
Kostakoglu, L.; Hardoff, R.; Mirtcheva, R.; Goldsmith, S.J. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics, 2004, 24, 1411-1431.
[20]
Corrigan, A.J.; Schleyer, P.J.; Cook, G.J. Pitfalls and artifacts in the use of PET/CT in oncology imaging. Semin. Nucl. Med., 2015, 45, 481-499.
[21]
Flukes, S.; Lenzo, N.; Moschilla, G.; Sader, C. Positron emission tomography-positive thyroid nodules: rate of malignancy and histological features. ANZ J. Surg., 2016, 86, 487-491.
[22]
Cook, G.J.; Maisey, M.N.; Fogelman, I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur. J. Nucl. Med., 1999, 26, 1363-1378.
[23]
Calabria, F.F.; Chiaravalloti, A.; Jaffrain-Rea, M.L.; Zinzi, M.; Sannino, P.; Minniti, G.; Rubello, D.; Schillaci, O. 18F-DOPA PET/CT physiological distribution and pitfalls: experience in 215 patients. Clin. Nucl. Med., 2016, 41, 753-760.
[24]
Calabria, F.; Chiaravalloti, A.; Cicciò, C.; Gangemi, V.; Gullà, D.; Rocca, F.; Gallo, G.; Cascini, G.L.; Scillacio, O. PET/CT with 18F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience. Nucl. Med. Biol., 2017, 51, 40-54.
[25]
Calabria, F.; Gallo, G.; Schillaci, O.; Cascini, G.L. Bio-distribution, imaging protocols and diagnostic accuracy of pet with tracers of lipogenesis in imaging prostate cancer: a comparison between 11C-choline, 18Ffluoroethylcholine and 18F-methylcholine. Curr. Pharm. Des., 2015, 21, 4738-4747.
[26]
Beheshti, M.; Haroon, A.; Bomanji, J.B.; Langsteger, W. Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls. PET Clin., 2014, 9, 299-306.
[27]
Welle, C.L.; Cullen, E.L.; Peller, P.J.; Lowe, V.J.; Murphy, R.C.; Johnson, G.B.; Binkovitz, L.A. 11C-choline PET/CT in recurrent prostate cancer and nonprostatic neoplastic processes. Radiographics, 2016, 36, 279-292.
[28]
Kirchner, J.; Schaarschmidt, B.M.; Sawicki, L.M.; Heusch, P.; Hautzel, H.; Ermert, J.; Rabenalt, R.; Antoch, G.; Buchbender, C. Evaluation of practical interpretation hurdles in 68Ga-PSMA PET/CT in 55 patients: physiological tracer distribution and incidental tracer uptake. Clin. Nucl. Med., 2017, 42, e322-e327.
[29]
Vellani, C.; Hodolič, M.; Chytiris, S.; Trifirò, G.; Rubello, D.; Colletti, P.M. Early and delayed 18F-FCH PET/CT imaging in parathyroid adenomas. Clin. Nucl. Med., 2017, 42, 143-144.
[30]
Afshar-Oromieh, A.; Wolf, M.B.; Kratochwil, C.; Giesel, F.L.; Combs, S.E.; Dimitrakopoulou-Strauss, A.; Gnirs, R.; Roethke, M.C.; Schlemmer, H.P.; Haberkorn, U. Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: initial results. Neuro-oncol., 2015, 17, 312-319.
[31]
Gerster-Gilliéron, K.; Forrer, F.; Maecke, H.; Mueller-Brand, J.; Merlo, A.; Cordier, D. 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J. Nucl. Med., 2015, 56, 1748-1751.
[32]
Pfob, C.H.; Ziegler, S.; Graner, F.P.; Köhner, M.; Schachoff, S.; Blechert, B.; Wester, H.J.; Scheidhauer, K.; Schwaiger, M.; Maurer, T.; Eiber, M. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43, 1962-1970.
[33]
Grubmüller, B.; Baum, R.P.; Capasso, E.; Singh, A.; Ahmadi, Y.; Knoll, P.; Floth, A.; Righi, S.; Zandieh, S.; Meleddu, C.; Shariat, S.F.; Klingler, H.C.; Mirzaei, S. 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: first in-human studies. Cancer Biother. Radiopharm., 2016, 31, 277-286.
[34]
Prasad, V.; Steffen, I.G.; Diederichs, G.; Makowski, M.R.; Wust, P.; Brenner, W. Biodistribution of [(68)Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol. Imaging Biol., 2016, 18, 428-436.
[35]
Demirci, E.; Sahin, O.E.; Ocak, M.; Akovali, B.; Nematyazar, J.; Kabasakal, L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl. Med. Commun., 2016, 37, 1169-1179.
[36]
Thomas, L.; Balmus, C.; Ahmadzadehfar, H.; Essler, M.; Strunk, H.; Bundschuh, R.A. Assessment of bone metastases in patients
with prostate cancer-a comparison between 99mTc-Bonescintigraphy
and 68Ga-PSMA PET/CT. Pharmaceuticals(Basel), 2017, 31, 10(3), pii: E68.
[37]
Blazak, J.K.; Thomas, P. Paget disease: a potential pitfall in psma pet for prostate cancer. Clin. Nucl. Med., 2016, 41, 699-700.
[38]
Schillaci, O.; Calabria, F.; Tavolozza, M.; Cicciò, C.; Carlani, M.; Caracciolo, C.R.; Danieli, R.; Orlacchio, A.; Simonetti, G. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl. Med. Commun., 2010, 31, 39-45.
[39]
Hisatomi, Y.; Okumura, K.; Nakamura, K.; Matsumoto, S.; Satoh, A.; Nagano, K.; Yamamoto, T.; Endo, F. Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages. Hepatology, 2004, 39, 667-675.
[40]
Han, X.D.; Liu, C.; Liu, F.; Xie, Q.H.; Liu, T.L.; Guo, X.Y.; Xu, X.X.; Yang, X.; Zhu, H.; Yang, Z. 64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model. Oncotarget, 2017, 8, 74159-74169.
[41]
Alt, K.; Wiehr, S.; Ehrlichmann, W.; Reischl, G.; Wolf, P.; Pichler, B.J.; Elsässer-Beile, U.; Bühler, P. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate, 2010, 15, 1413-1421.
[42]
Andreozzi, E.M.; Torres, J.B.; Sunassee, K.; Dunn, J.; Walker-Samuel, S.; Szanda, I.; Blower, P.J. Studies of copper trafficking in a mouse model of Alzheimer’s disease by positron emission tomography: comparison of 64Cu acetate and 64CuGTSM. Metallomics, 2017, 15, 1622-1633.
[43]
Ishihara, N.; Matsushiro, T. Biliary and urinary excretion of metals in humans. Arch. Environ. Health, 1986, 41, 324-330.
[44]
Hofman, M.S.; Iravani, A. Gallium-68 prostate-specific membrane antigen PET imaging. PET Clin., 2017, 12, 219-234.
[45]
Gourni, E.; Canovas, C.; Goncalves, V.; Denat, F.; Meyer, P.T.; Maecke, H.R. (R)-NODAGA-PSMA: a versatile precursor for radiometal labeling and nuclear imaging of psma-positive tumors. PLoS One, 2015, 10e0145755
[46]
Haroon, A.; Zanoni, L.; Celli, M.; Zakavi, R.; Beheshti, M.; Langsteger, W.; Fanti, S.; Emberton, M.; Bomanji, J. Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants. Nucl. Med. Commun., 2015, 36, 1065-1075.
[47]
Schillaci, O.; Calabria, F.; Tavolozza, M.; Caracciolo, C.R.; Finazzi-Agrò, E.; Miano, R.; Orlacchio, A.; Danieli, R.; Simonetti, G. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 589-596.
[48]
Spick, C.; Herrmann, K.; Czernin, J. Evaluation of Prostate Cancer with 11C-Acetate PET/CT. J. Nucl. Med., 2016, 57, 30S-37S.
[49]
Schuster, D.M.; Votaw, J.R.; Nieh, P.T.; Yu, W.; Nye, J.A.; Master, V.; Bowman, F.D.; Issa, M.M.; Goodman, M.M. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J. Nucl. Med., 2007, 8, 56-63.
[50]
Teoh, E.J.; Tsakok, M.T.; Bradley, K.M.; Hyde, K.; Subesinghe, M.; Gleeson, F.V. Recurrent malignant melanoma detected on 18F-fluciclovine PET/CT imaging for prostate cancer. Clin. Nucl. Med., 2017, 42, 803-804.
[51]
Vardhanabhuti, V.; Lo, A.W.; Lee, E.Y.; Law, S.Y. Dual-tacer PET/CT using 18F-FDG and 11C-Acetate in gastric adenocarcinoma with liver metastasis. Clin. Nucl. Med., 2016, 41, 864-865.
[52]
Calabria, F.; D’Auria, S.; Sannino, P.; Schillaci, O. A case of thymoma detected by 18F-choline positron emission tomography/computed tomography. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 602.
[53]
Anconina, R. Hod. N.; Levin, D.; Ezroh Kazap, D., Lantsberg, S. incidental detection of metastatic malignant melanoma on 68Ga-prostate-specific membrane antigen PET/CT imaging: Correlative imaging with FDG PET/CT and review of the literature. Clin. Nucl. Med., 2018, 43, 204-206.
[54]
Oh, G.; Miles, K. Subacute cerebellar infarction with uptake on 68Ga-Prostate-specific membrane antigen PET/CT. Clin. Nucl. Med., 2018, 43, 134-135.
[55]
Jochumsen, M.R.; Gormsen, L.C.; Nielsen, G.L. 68Ga-PSMA avid primary adenocarcinoma of the lung with complementary low 18F-FDG uptake. Clin. Nucl. Med., 2018, 43, 117-119.
[56]
Jochumsen, M.R.; Bouchelouche, K. Intense 68Ga-PSMA Uptake in Diverticulum of the Sigmoid Colon. Clin. Nucl. Med., 2018, 43, 110-111.
[57]
Bilgin, R.; Ergül, N.; Çermik, T.F. Incidental meningioma mimicking metastasis of prostate adenocarcinoma in 68Ga-labeled PSMA ligand. Nucl. Med. Commun., 2016, 37, 1197-1205.
[58]
Calabria, F. Fifty shades of meningioma: Challenges and perspectives of different PET molecular probes. Clin. Transl. Imaging, 2017, 5, 403-405.
[59]
Green, M.A.; Eitel, J.A.; Fletcher, J.W.; Mathias, C.J.; Tann, M.A.; Gardner, T.; Koch, M.O.; Territo, W.; Polson, H.; Hutchins, G.D. Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer. Nucl. Med. Biol., 2017, 46, 32-35.
[60]
Calabria, F.; Chiaravalloti, A.; Schillaci, O. (18)F-choline PET/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer. Clin. Nucl. Med., 2014, 39, 122-130.
